HK1124336A1 - Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties - Google Patents

Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties

Info

Publication number
HK1124336A1
HK1124336A1 HK09103859.5A HK09103859A HK1124336A1 HK 1124336 A1 HK1124336 A1 HK 1124336A1 HK 09103859 A HK09103859 A HK 09103859A HK 1124336 A1 HK1124336 A1 HK 1124336A1
Authority
HK
Hong Kong
Prior art keywords
atpase
deuterated
gastric
inhibitors
therapeutic properties
Prior art date
Application number
HK09103859.5A
Other languages
English (en)
Inventor
Thomas Gant
Sepehr Sarshar
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1124336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of HK1124336A1 publication Critical patent/HK1124336A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK09103859.5A 2005-10-06 2009-04-27 Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties HK1124336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72416005P 2005-10-06 2005-10-06
US74131605P 2005-12-01 2005-12-01
PCT/US2006/038819 WO2007041630A1 (en) 2005-10-06 2006-10-04 Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties

Publications (1)

Publication Number Publication Date
HK1124336A1 true HK1124336A1 (en) 2009-07-10

Family

ID=37603090

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09103859.5A HK1124336A1 (en) 2005-10-06 2009-04-27 Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties

Country Status (10)

Country Link
US (3) US7598273B2 (pt)
EP (1) EP1934201A1 (pt)
JP (1) JP2009511481A (pt)
CN (1) CN101309917B (pt)
AU (1) AU2006299424A1 (pt)
BR (1) BRPI0617987A2 (pt)
CA (1) CA2624179A1 (pt)
HK (1) HK1124336A1 (pt)
IL (1) IL190331A0 (pt)
WO (1) WO2007041630A1 (pt)

Families Citing this family (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683177B2 (en) * 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
MX2008011868A (es) * 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
BRPI0711228A2 (pt) * 2006-05-26 2012-06-19 Auspex Pharmaceuticals Inc "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto"
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
US20080280927A1 (en) * 2006-10-20 2008-11-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
MX2009003941A (es) * 2006-10-20 2009-04-24 Concert Pharmaceuticals Inc Derivados de 3-(dihidro-1h-pirazolo[4,3-d]pirimidin-5-il)-4-propox ibencenosulfonamida y metodos de uso.
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
CA2703011A1 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
WO2008076949A2 (en) * 2006-12-15 2008-06-26 Concert Pharmaceuticals Inc. Quinazoline derivatives and methods of treatment
US20090325976A1 (en) * 2006-12-21 2009-12-31 Concert Pharmaceuticals Inc. Prostacyclin derivatives
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008097468A2 (en) * 2007-02-02 2008-08-14 Concert Pharmaceuticals, Inc. Selective endothelin type-a antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
WO2008106125A2 (en) * 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
ES2559838T3 (es) * 2007-03-16 2016-02-16 Concert Pharmaceuticals, Inc. Inhibidores de proteína de transferencia de ésteres de colesterol
WO2008130863A2 (en) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008127640A2 (en) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US8349817B2 (en) * 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
ES2401914T3 (es) * 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
PT2345653E (pt) 2007-05-01 2013-04-01 Concert Pharmaceuticals Inc Compostos de morfinano
HUE063526T2 (hu) 2007-05-01 2024-01-28 Concert Pharmaceuticals Ind Inc Morfinvegyületek
US7608737B2 (en) * 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
WO2008141021A1 (en) * 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
US20080306151A1 (en) * 2007-06-11 2008-12-11 Protia, Llc Deuterium-enriched fenofibrate
ES2356334T3 (es) * 2007-06-12 2011-04-07 Concert Pharmaceuticals, Inc. Derivados de azapéptidos como inhibidores de la proteasa vih.
AU2008266124A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20090005366A1 (en) * 2007-06-19 2009-01-01 Protia, Llc Deuterium-enriched olanzapine
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
US20080319007A1 (en) * 2007-06-21 2008-12-25 Protia, Llc Deuterium-enriched montelukast
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
EP2190841B1 (en) * 2007-08-14 2013-05-15 Concert Pharmaceuticals Inc. Substituted oxazolidinone derivatives
US20090062393A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pregabalin
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
US20090062561A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched latanoprost
US20090062374A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched lasofoxifene
US20090062385A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched fesoterodine
US20090062299A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched doxazosin
US20090062283A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched linezolid
US20090062316A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pelitrexol
US20090062305A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched cetirizine
US20090069413A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched olopatadine
US20090069410A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched paclitaxel
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090069339A1 (en) * 2007-09-11 2009-03-12 Protia, Llc Deuterium-enriched ciprofloxacin
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
WO2009035662A1 (en) * 2007-09-12 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20090076165A1 (en) * 2007-09-12 2009-03-19 Protia, Llc Deuterium-enriched memantine
US20090076118A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched saxagliptin
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US20090075965A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched amoxicilin
US20090076161A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bupropion
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US7919516B2 (en) * 2007-09-13 2011-04-05 Protia, Llc Deuterium-enriched ondansetron
US20090076112A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched eltrombopag
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US20090075991A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched efavirenz
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20090076148A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched pravastatin
US20090076102A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched muraglitazar
US20090076028A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched itraconazole
US20090075944A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ibandronate
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
US20090076163A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched dapoxetine
US20090076040A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched valganciclovir
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090076126A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched enalapril
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
US20090076154A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched vorinostat
US20090076159A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
US20090076011A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched tirapazamine
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
US20090075997A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched satavaptan
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090082459A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched guanfacine
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
US20090082335A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched oxcarbazepine
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US20090143363A1 (en) * 2007-10-15 2009-06-04 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
CA2703591C (en) * 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
US8338425B2 (en) * 2007-12-10 2012-12-25 Concert Pharmaceuticals, Inc. Heterocyclic kinase inhibitors
WO2009079637A1 (en) * 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
WO2009094216A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Derivatives of gefitinib
CN101492464B (zh) * 2008-01-25 2011-01-12 山东轩竹医药科技有限公司 含有二氧杂环庚烷并吡啶的巯基咪唑并吡啶衍生物
CN101492452B (zh) * 2008-01-25 2010-11-17 山东轩竹医药科技有限公司 含有二氧杂环庚烷并吡啶的巯基苯并咪唑衍生物
US20090209550A1 (en) * 2008-02-20 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted triazolopyridines
BRPI0908107A2 (pt) * 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
DK2276774T3 (en) 2008-03-14 2016-11-28 Retrotope Inc Drugs that modulate genome methylation.
US10029956B2 (en) * 2008-03-14 2018-07-24 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
KR20110006675A (ko) * 2008-04-09 2011-01-20 콘서트 파마슈티컬즈, 인크. 3-(2-히드록시-5-메틸페닐)-ｎ,ｎ-디이소프로필-3-페닐프로필아민의 중수소로 표지된 유도체 및 이의 사용 방법
US20100120786A1 (en) * 2008-04-17 2010-05-13 Concert Pharmaceuticals, Inc. Piperazine Derivatives
WO2009128947A1 (en) * 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
WO2009145852A1 (en) * 2008-04-17 2009-12-03 Concert Pharmaceuticals, Inc. Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
JP5183808B2 (ja) 2008-08-29 2013-04-17 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロ−ピリダジン誘導体
US8541419B2 (en) * 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
US20100105755A1 (en) * 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
WO2010033511A1 (en) * 2008-09-16 2010-03-25 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2010033270A1 (en) * 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
AU2009293123B2 (en) 2008-09-19 2013-12-19 Concert Pharmaceuticals Inc. Morphinan compounds
US20100087455A1 (en) * 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
RU2562583C2 (ru) 2008-10-17 2015-09-10 Сигничер Терапьютикс, Инк. Фармацевтические композиции с уменьшенным высвобождением фенольных опиоидов
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20100137215A1 (en) * 2008-11-25 2010-06-03 Concert Pharmaceuticals Inc. Novel tetrahydro-1h-pyrido[4,3-b]indoles
US20110313004A1 (en) * 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20100143354A1 (en) * 2008-12-04 2010-06-10 Auspex Pharmaceuticals, Inc. Triazine dna modifiers
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
MX339096B (es) * 2008-12-23 2016-05-11 Aquilus Pharmaceuticals Inc Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
EP2396312A1 (en) * 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
US20110053961A1 (en) * 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US20100291151A1 (en) * 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
ES2664984T3 (es) 2009-04-22 2018-04-24 SMA Therapeutics, Inc. Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
US8461197B2 (en) 2009-04-23 2013-06-11 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US20100305173A1 (en) * 2009-04-30 2010-12-02 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2010135579A1 (en) 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
WO2010144499A2 (en) * 2009-06-09 2010-12-16 Medolution Limited Urea derivatives as kinase inhibitors
ES2469849T3 (es) 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
US8501738B2 (en) * 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
JP2012533567A (ja) * 2009-07-17 2012-12-27 ライジェル ファーマシューティカルズ， インコーポレイテッド 重水素化２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
US20110082147A1 (en) * 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
US8637524B2 (en) * 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8618116B2 (en) * 2009-08-03 2013-12-31 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
US8557815B2 (en) * 2009-08-14 2013-10-15 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
EP2473052A4 (en) * 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc SUBSTITUTED XANTHINE DERIVATIVES
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
MX348262B (es) 2009-09-08 2017-06-05 Signature Therapeutics Inc * Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US8278460B2 (en) * 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
RU2012121847A (ru) * 2009-10-28 2013-12-10 Анадис Фармасьютикалз, Инк. Дейтерированные соединения 5, 6-дигидро-1н-пиридин-2-она
US20120220595A1 (en) 2009-11-12 2012-08-30 OSI Pharmaceuticals, LLC Deuterated Tyrosine Kinase Inhibitors
US8471034B2 (en) * 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
TW201129362A (en) * 2009-11-21 2011-09-01 Hoffmann La Roche Heterocyclic antiviral compounds
US20110178180A1 (en) * 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2539347A2 (en) * 2010-02-24 2013-01-02 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
US20130109707A1 (en) * 2010-03-01 2013-05-02 Concert Pharmaceuticals ,Inc. Fluorouracil derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) * 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2560490A1 (en) * 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
AU2010351605C1 (en) * 2010-04-21 2015-08-06 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
EP2611759A1 (en) * 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2012096887A2 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
CN103619334A (zh) * 2011-01-19 2014-03-05 朱红文 噻唑烷衍生物和其治疗用途
US8759394B2 (en) 2011-02-14 2014-06-24 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012122028A2 (en) 2011-03-04 2012-09-13 Concert Pharmaceuticals Inc. Pyrazinoisoquinoline compounds
RU2608305C2 (ru) 2011-03-09 2017-01-17 Сигничер Терапьютикс, Инк. Пролекарства действующих веществ гетероциклическими линкерами
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CA2860489C (en) * 2012-02-08 2019-11-12 Merck Patent Gmbh Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
US9328113B2 (en) 2012-04-13 2016-05-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US20150197525A1 (en) * 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US9181190B2 (en) 2012-07-04 2015-11-10 Concert Pharmaceuticals, Inc. Deuterated vercirnon
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
KR20150038486A (ko) 2012-07-30 2015-04-08 콘서트 파마슈티컬즈, 인크. 중수소화된 아이브루티닙
EP3492472A1 (en) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
EP2888222A1 (en) * 2012-08-22 2015-07-01 Concert Pharmaceuticals Inc. Deuterated 4-hydroxybutyric acid analogs
CN104755472A (zh) * 2012-09-04 2015-07-01 细胞基因公司 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法
WO2014039748A1 (en) * 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
JP2015534989A (ja) 2012-10-22 2015-12-07 コンサート ファーマシューティカルズ インコーポレイテッド ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
AU2014205472B2 (en) 2013-01-09 2018-05-10 Concert Pharmaceuticals Inc. Deuterated momelotinib
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2014121036A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CN103204819B (zh) * 2013-04-15 2015-03-11 公安部物证鉴定中心 氘代地西泮及其制备方法
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
US9732031B2 (en) 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2015209330A1 (en) * 2014-01-27 2016-07-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3102190A4 (en) 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
BR112016023162B1 (pt) 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
DK3157926T3 (da) * 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
AU2015312134A1 (en) * 2014-09-02 2017-03-23 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
CA2966452A1 (en) * 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
HUE045477T2 (hu) * 2015-04-02 2019-12-30 Merck Patent Gmbh Imidazolonilkinolinok és ezek alkalmazása ATM kináz inhibitorként
US10683305B2 (en) * 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CN107698620A (zh) * 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
AU2015399642B2 (en) * 2015-06-26 2020-04-09 Chongqing Dikang Erle Pharma Co. Ltd. Novel phosphodiesterase type-5 inhibitor and application thereof
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
AU2016327603B2 (en) 2015-09-25 2021-04-22 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR potentiators
CN107207469B (zh) * 2015-10-21 2018-09-25 纽弗姆制药有限公司 用于治疗血液恶性肿瘤的氘代化合物以及其组合物和方法
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
CN108541255B (zh) * 2016-02-02 2019-06-14 深圳市塔吉瑞生物医药有限公司 一种甾体类化合物及包含该化合物的组合物及其用途
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
CN110072518B (zh) 2016-10-12 2021-10-26 细胞内治疗公司 无定形固体分散体
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2019011329A (es) 2017-03-24 2019-12-02 Intra Celular Therapies Inc Composiciones novedosas y metodos.
IL270680B (en) * 2017-05-16 2022-06-01 Vertex Pharma Deuterium-converted pyridone amides and their prodrugs as sodium channel modulators
CN109498811A (zh) * 2017-09-15 2019-03-22 江苏吉贝尔药业股份有限公司 一种含钾离子竞争性酸阻滞剂和非甾体抗炎药的复方制剂
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
IL274763B2 (en) 2017-12-01 2024-01-01 Vertex Pharma Methods for making cystic fibrosis transmembrane conductance modulator modulators
CN109456331B (zh) * 2017-12-22 2020-06-05 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
CN109575025B (zh) 2018-01-23 2020-09-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. INNOVATIVE USES
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4
US12076320B2 (en) * 2018-07-12 2024-09-03 Shenzhen Targetrx, Inc. Diarylpyrazole compound, composition comprising same, and use thereof
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
AU2019328528A1 (en) 2018-08-31 2021-03-18 Intra-Cellular Therapies, Inc. Novel methods
CN112512591B (zh) * 2018-09-26 2024-08-16 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
WO2020206367A1 (en) 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
KR20220029744A (ko) 2019-07-07 2022-03-08 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규 방법
CN110194773B (zh) * 2019-07-26 2019-11-22 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
WO2023092044A2 (en) 2021-11-17 2023-05-25 Terran Biosciences, Inc. Phenethylamine compounds salts, polymorphic forms and methods of use thereof
CN116726011A (zh) * 2022-03-04 2023-09-12 丽珠医药集团股份有限公司 艾普拉唑用于调节消化道微生态的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DK0382489T3 (da) 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ATE372966T1 (de) * 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
ATE314388T1 (de) * 1997-10-08 2006-01-15 Isotechnika Inc Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
SI1100469T1 (pt) 1998-07-28 2005-08-31 Takeda Pharmaceutical
US6191148B1 (en) 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
US6166213A (en) 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
EP1134290A3 (en) 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US7396841B2 (en) 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
KR100887912B1 (ko) 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1910293A1 (en) * 2005-07-26 2008-04-16 Nycomed GmbH Isotopically substituted proton pump inhibitors
EP1912947A1 (en) * 2005-07-26 2008-04-23 Nycomed GmbH Isotopically substituted pantoprazole
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
US20080033011A1 (en) 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
WO2007023135A1 (en) 2005-08-22 2007-03-01 Nycomed Gmbh Isotopically substituted benzimidazole derivatives
WO2007039464A1 (en) 2005-09-22 2007-04-12 Nycomed Gmbh Isotopically substituted imidazopyridine derivatives for the treatment of gastrointestinal disorders
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20070281894A1 (en) 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US8466166B2 (en) 2006-09-21 2013-06-18 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008127640A2 (en) 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008130863A2 (en) 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
JP2010524972A (ja) 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
US20090076089A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched pantoprazole
US20090258897A1 (en) * 2008-04-11 2009-10-15 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles

Also Published As

Publication number Publication date
IL190331A0 (en) 2009-09-22
US7598273B2 (en) 2009-10-06
US20090209592A1 (en) 2009-08-20
EP1934201A1 (en) 2008-06-25
WO2007041630A1 (en) 2007-04-12
CN101309917B (zh) 2013-09-11
US20070082929A1 (en) 2007-04-12
BRPI0617987A2 (pt) 2011-08-16
AU2006299424A1 (en) 2007-04-12
JP2009511481A (ja) 2009-03-19
US20090215831A1 (en) 2009-08-27
CA2624179A1 (en) 2007-04-12
CN101309917A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
HK1124336A1 (en) Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
IL248204A0 (en) Combined treatment of tumors expressing 38cd
IL243376A0 (en) Antagonistic antibody against epha2 for cancer treatment
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
GB0602178D0 (en) Therapeutic treatment
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL197315A0 (en) Treatment of cancer
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
EP2257647A4 (en) MICRO-RNA-BASED PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF GAS CANCER
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
EP2083774A4 (en) THERAPEUTIC INTRAVAGINAL DEVICES AND METHOD
IL188430A0 (en) Treatment of tumors
GB0608655D0 (en) Therapeutic Treatment
GB0600692D0 (en) Well treatment
AP2008004569A0 (en) IGR-IR antagonists as adjuvants for treatment of prostrate cancer
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2004154A4 (en) THERAPEUTIC BELT
GB0610909D0 (en) Therapeutic treatment
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
IL192031A0 (en) Use of cicletanine and other furopyridines for treatment of hypertension
GB0607952D0 (en) Novel treatment
ZA200904478B (en) Novel therapeutic use for treating leukaemia
EP2142256A4 (en) TREATMENT OF ADIPOSITAS
EP2164494A4 (en) Methods of Treatment